Ethical considerations in industry-sponsored Multiregional Clinical Trials

被引:7
|
作者
Ibia, Ekopimo [1 ]
Binkowitz, Bruce [1 ]
Saillot, Jean-Louis [1 ]
Talerico, Steven [1 ]
Koerner, Chin [2 ]
Ferreira, Irene [3 ]
Agarwal, Anupam [4 ]
Metz, Craig [4 ]
Maman, Marianne [2 ]
机构
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Novartis Pharmaceut, Rockville, MD USA
[3] Amgen Inc, Cambridge, Cambs, England
[4] GlaxoSmithKline Plc, Collegeville, PA USA
关键词
ethical principles; Multiregional Clinical Trials; global trials; post-trial benefits; informed consent process; data monitoring; DEVELOPING-COUNTRIES; GLOBALIZATION;
D O I
10.1002/pst.458
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the last several decades, the scientific and ethics communities have addressed important ethical issues in medical research, resulting in the elaboration and adoption of concepts, guidelines, and codes. Ethical issues in the conduct of Multiregional Clinical Trials have attracted significant attention mainly in the last two decades. With the globalization of clinical research and the rapid expansion to countries with a limited tradition of biomedical research, sponsors must proactively address local ethical issues, the adequacy of oversight as well as the applicability and validity of data, and scientific conclusions drawn from diverse patient populations. This paper highlights some core ethical principles and milestones in medical research, and, from an industry perspective, it discusses ethical issues that the clinical trial team may face when conducting Multiregional Clinical Trials (MRCT, clinical trials conducted at sites located across multiple geographic regions of the world). This paper further highlights the areas of consensus and controversies and proposes points to consider. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:230 / 241
页数:12
相关论文
共 50 条
  • [31] Carbon footprint of industry-sponsored late-stage clinical trials
    Mackillop, Neil
    Shah, Jayesh
    Collins, Michael
    Costelloe, Thomas
    Ohman, Daniel
    [J]. BMJ OPEN, 2023, 13 (08):
  • [32] At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products
    Varmaghani, Mehdi
    Heidari, Elham
    Reiner, Zeljko
    Sahebkar, Amirhossein
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1193 - 1195
  • [33] The Costs of Industry-Sponsored Drug Trials in Canada
    Tran, Dat T.
    Akpinar, Like
    Jacobs, Philip
    [J]. PHARMACOECONOMICS-OPEN, 2020, 4 (02) : 353 - 359
  • [34] The Costs of Industry-Sponsored Drug Trials in Canada
    Dat T. Tran
    Ilke Akpinar
    Philip Jacobs
    [J]. PharmacoEconomics - Open, 2020, 4 : 353 - 359
  • [35] Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials
    Devaiah, Anand
    Murchison, Charles
    [J]. LARYNGOSCOPE, 2016, 126 (09): : E300 - E303
  • [36] Physician remuneration in industry-sponsored clinical trials: the case for standardized clinical trial budgets
    Ferris, LE
    Naylor, CD
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (08) : 883 - 886
  • [37] An editor's considerations in publishing industry-sponsored studies
    Droller, Michael J.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (03) : 149 - 154
  • [38] Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes
    Farrell, Ryan
    Bethin, Kathleen
    Klingensmith, Georgeanna
    Tamborlane, William V.
    Gubitosi-Klug, Rose
    [J]. PEDIATRIC DIABETES, 2017, 18 (07) : 574 - 578
  • [39] Uniform guidelines for reporting COI within industry-sponsored clinical trials (ISCT)
    Hussey, Valerie
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (12) : 1496 - 1497
  • [40] Implementation of an authorship algorithm for industry-sponsored clinical trials at Celgene: a case study
    Fusaro, Gina
    Matheis, Robert
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 : 12 - 12